AlgoTx

AlgoTx is a Paris-based biotechnology company dedicated to developing innovative solutions for complex pain conditions that currently lack proven and approved therapies. The company focuses on creating treatments tailored to the specific needs of patients suffering from difficult-to-treat pain. AlgoTx's flagship product, ATX01, is in Phase 2 clinical development for Peripheral Neuropathy, a condition often experienced by chemotherapy patients. The ACT study for ATX01 is ongoing in the US and Europe. Additionally, the FDA and German regulatory authority BfArM have approved a Phase 2 Proof of Concept study for ATX01 in erythromelalgia, a rare and painful disease. This EASE study is set to commence in Q2 2023 in the US and Germany. AlgoTx employs a topical administration method to directly block pain messaging in the nerve fibers of the skin, minimizing systemic side effects typically associated with oral or intravenous drugs. The company serves patients with complex pain conditions, operating in the biotech and pharmaceutical markets. Its business model revolves around the research, development, and eventual commercialization of novel pain treatments. Revenue is generated through the successful development and licensing of its pharmaceutical products.

Keywords: biotech, complex pain, Peripheral Neuropathy, erythromelalgia, ATX01, Phase 2 clinical, topical administration, chemotherapy, pain management, innovative treatments.